Steven Lo is Chief Executive Officer and member of the Board of Directors of Vaxart, a clinical-stage public biotechnology company developing a range of oral recombinant vaccines. He has 30 years of experience in life sciences, including 13 years of C-level experience in publicly traded biotech companies.

From 2022 to 2024, Mr. Lo was the CEO of Valitor, a private biotechnology company and from 2019 to 2022, he was CEO of Zosano Pharma, a publicly traded biotechnology company. From 2015 to 2019, he was the Chief Commercial Officer at Puma Biotechnology where he built and led the worldwide commercialization and business development of the company’s first product. Previously, he was Chief Commercial Officer of Corcept Therapeutics, where he formed the commercial organization to launch the company’s first product.

Earlier in his career, he spent over a decade at Genentech, the US subsidiary of Roche, in a variety of leadership roles of increasing responsibility in market access, marketing and sales, and drug development, working in numerous therapeutic areas, including oncology, endocrinology and other specialty therapeutics.

Mr. Lo started his career in the pharmaceutical industry at AstraZeneca after holding positions in finance and operations at Kaiser Permanente. He obtained a Masters in Health Administration from the University of Southern California and a B.S. in Microbiology from the University of California, Davis.

Back